Cehajic-Kapetanovic Jasmina, Kwartz Jeff
Academic Department of Ophthalmology, Manchester Royal Eye Hospital, Manchester, UK.
J Pediatr Ophthalmol Strabismus. 2010 Nov-Dec;47(6):356-60. doi: 10.3928/01913913-20100118-01. Epub 2010 Jan 22.
To report the use of Augmentin Duo 400/57 (GlaxoSmithKline, Middlesex, UK) in the treatment of childhood blepharokeratoconjunctivitis (BKC).
This is a retrospective interventional case series. The case notes of 7 consecutive patients treated with Augmentin Duo 400/57 for BKC during 18 months were reviewed. Diagnostic criteria for BKC were blepharitis including recurrent chalazia and meibomian gland dysfunction, eyelid margin telangiectasia and facial rosacea, recurrent episodes of chronic red eye, photophobia, watering, punctate superficial keratopathy, corneal neovascularization, and corneal ulcers.
Seven children (age range: 6 to 14 years) were diagnosed as having BKC. All children received systemic Augmentin Duo 400/57 and showed considerable improvement within the first month of therapy. Six children had no recurrences during a mean follow-up of 6 months. No patients experienced any side effects from this treatment.
Augmentin Duo 400/57 has not previously been reported in the treatment of BKC in children. In this case series, Augmentin Duo 400/57 proved to be at least as effective as current treatments with systemic erythromycin or doxycycline with the advantage of a twice-daily dosage and a superior side-effect profile.
报告用奥格门汀 Duo 400/57（葛兰素史克公司，英国米德尔塞克斯）治疗儿童睑缘角结膜炎（BKC）的情况。
这是一项回顾性干预病例系列研究。回顾了18个月内连续7例接受奥格门汀 Duo 400/57治疗BKC的患者的病历。BKC的诊断标准包括睑缘炎，如复发性睑板腺囊肿和睑板腺功能障碍、睑缘毛细血管扩张和面部酒渣鼻、慢性红眼反复发作、畏光、流泪、点状浅层角膜病变、角膜新生血管和角膜溃疡。
7名儿童（年龄范围：6至14岁）被诊断为患有BKC。所有儿童均接受全身性奥格门汀 Duo 400/57治疗，且在治疗的第一个月内病情有显著改善。6名儿童在平均6个月的随访期间无复发。无患者因该治疗出现任何副作用。
此前尚无奥格门汀 Duo 400/57用于治疗儿童BKC的报道。在本病例系列中，奥格门汀 Duo 400/57被证明至少与目前全身性使用红霉素或强力霉素的治疗效果相当，且具有每日给药两次及副作用较小的优势。
